Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmeris… Read more
Fagron NV (ARSUF) - Net Assets
Latest net assets as of June 2025: $505.40 Million USD
Based on the latest financial reports, Fagron NV (ARSUF) has net assets worth $505.40 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.12 Billion) and total liabilities ($613.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $505.40 Million |
| % of Total Assets | 45.16% |
| Annual Growth Rate | 11.33% |
| 5-Year Change | 96.01% |
| 10-Year Change | N/A |
| Growth Volatility | 45.84 |
Fagron NV - Net Assets Trend (2013–2024)
This chart illustrates how Fagron NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fagron NV (2013–2024)
The table below shows the annual net assets of Fagron NV from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $505.36 Million | +8.07% |
| 2023-12-31 | $467.63 Million | +14.44% |
| 2022-12-31 | $408.63 Million | +25.55% |
| 2021-12-31 | $325.47 Million | +26.24% |
| 2020-12-31 | $257.82 Million | +4.62% |
| 2019-12-31 | $246.44 Million | +17.51% |
| 2018-12-31 | $209.72 Million | +13.43% |
| 2017-12-31 | $184.88 Million | +20.94% |
| 2016-12-31 | $152.88 Million | +336.02% |
| 2015-12-31 | $-64.77 Million | -134.11% |
| 2014-12-31 | $189.87 Million | +22.36% |
| 2013-12-31 | $155.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fagron NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 211.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $264.87 Million | 52.83% |
| Other Components | $236.48 Million | 47.17% |
| Total Equity | $501.35 Million | 100.00% |
Fagron NV Competitors by Market Cap
The table below lists competitors of Fagron NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
$1.30 Billion |
|
The Gunma Bank Ltd
OTCGREY:GMBKF
|
$1.30 Billion |
|
Nationwide Building Society
LSE:NBS
|
$1.30 Billion |
|
Coca-Cola Bottlers Japan Holdings Inc
OTCGREY:CCOJF
|
$1.30 Billion |
|
De'Longhi S.p.A
OTCGREY:DELHF
|
$1.30 Billion |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
$1.30 Billion |
|
Fabege AB
ST:FABG
|
$1.30 Billion |
|
Amprius Technologies Inc.
NYSE:AMPX
|
$1.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fagron NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 463,722,000 to 501,354,000, a change of 37,632,000 (8.1%).
- Net income of 80,554,000 contributed positively to equity growth.
- Dividend payments of 21,046,000 reduced retained earnings.
- Share repurchases of 2,859,000 reduced equity.
- Other factors decreased equity by 19,017,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $80.55 Million | +16.07% |
| Dividends Paid | $21.05 Million | -4.2% |
| Share Repurchases | $2.86 Million | -0.57% |
| Other Changes | $-19.02 Million | -3.79% |
| Total Change | $- | 8.12% |
Book Value vs Market Value Analysis
This analysis compares Fagron NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $20.03 | x |
| 2016-12-31 | $0.00 | $20.03 | x |
| 2017-12-31 | $0.00 | $20.03 | x |
| 2018-12-31 | $0.00 | $20.03 | x |
| 2019-12-31 | $3.36 | $20.03 | x |
| 2020-12-31 | $3.50 | $20.03 | x |
| 2021-12-31 | $4.39 | $20.03 | x |
| 2022-12-31 | $5.52 | $20.03 | x |
| 2023-12-31 | $6.35 | $20.03 | x |
| 2024-12-31 | $6.88 | $20.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fagron NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.24%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 2.16x
- Recent ROE (16.07%) is above the historical average (10.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -21.18% | -9.37% | 0.43x | 5.31x | $-47.26 Million |
| 2014 | 10.49% | 3.63% | 0.46x | 6.30x | $923.06K |
| 2015 | 0.00% | -47.32% | 0.62x | 0.00x | $-195.58 Million |
| 2016 | -13.73% | -4.87% | 0.49x | 5.80x | $-35.54 Million |
| 2017 | 25.72% | 10.76% | 0.73x | 3.27x | $28.52 Million |
| 2018 | 20.64% | 9.01% | 0.69x | 3.32x | $21.90 Million |
| 2019 | 16.96% | 7.68% | 0.67x | 3.31x | $16.85 Million |
| 2020 | 23.55% | 10.72% | 0.74x | 2.97x | $34.29 Million |
| 2021 | 19.06% | 10.63% | 0.72x | 2.50x | $28.99 Million |
| 2022 | 17.29% | 10.18% | 0.70x | 2.41x | $29.35 Million |
| 2023 | 15.21% | 9.25% | 0.76x | 2.17x | $24.17 Million |
| 2024 | 16.07% | 9.24% | 0.80x | 2.16x | $30.42 Million |
Industry Comparison
This section compares Fagron NV's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fagron NV (ARSUF) | $505.40 Million | -21.18% | 1.21x | $1.30 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |